Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Voyager Therapeutics Inc | VYGR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.57 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.57 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 6.06 - 14.3398 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 7.57 | USD |
Voyager Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 410.51M | 54.30M | - | 250.01M | 132.33M | 2.44 | 3.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Voyager Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VYGR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.30 | 8.39 | 7.2831 | 7.64 | 598,973 | -0.73 | -8.80% |
| 1 Month | 9.89 | 10.66 | 7.2831 | 8.99 | 617,511 | -2.32 | -23.46% |
| 3 Months | 7.55 | 10.66 | 7.08 | 8.87 | 659,649 | 0.02 | 0.26% |
| 6 Months | 6.78 | 11.72 | 6.06 | 8.73 | 636,559 | 0.79 | 11.65% |
| 1 Year | 7.96 | 14.3398 | 6.06 | 9.47 | 555,191 | -0.39 | -4.90% |
| 3 Years | 4.71 | 14.3398 | 2.46 | 5.73 | 892,318 | 2.86 | 60.72% |
| 5 Years | 19.69 | 28.79 | 2.46 | 7.35 | 680,215 | -12.12 | -61.55% |
Voyager Therapeutics Description
| Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. |
